Structure Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GPCR Nasdaq 2836 structuretx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Structure Therapeutics Inc.

Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines? - Sep 30th, 2026 6:17 am
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? - Sep 23rd, 2026 8:11 am
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results - Sep 22nd, 2026 11:20 am
Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus - Sep 22nd, 2026 5:13 am
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’ - Sep 21st, 2026 11:29 pm
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious? - Sep 17th, 2026 9:08 am
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now? - Sep 17th, 2026 8:30 am
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes? - Sep 14th, 2026 8:37 am
Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal? - Sep 10th, 2026 5:46 pm
Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial - Sep 8th, 2026 11:29 am
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Sep 8th, 2026 7:23 am
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management - Sep 8th, 2026 6:00 am
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences - Sep 3rd, 2026 5:30 am
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity? - Aug 31st, 2026 8:00 am
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - Aug 26th, 2026 6:19 am
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - Aug 19th, 2026 9:46 am
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock? - Aug 17th, 2026 9:09 am
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1? - Aug 13th, 2026 7:42 am
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock? - Aug 12th, 2026 9:10 am
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - Aug 6th, 2026 2:05 pm